Intravenous Palifosfamide-tris in Combination With Etoposide and Carboplatin in Patients With Malignancies
| Status: | Archived |
|---|---|
| Conditions: | Lung Cancer, Ovarian Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | November 2010 |
| End Date: | July 2011 |
A Phase I Study of Intravenous (IV) Palifosfamide-tris Administered in Combination With IV Etoposide and IV Carboplatin in Patients With Malignancies for Which Etoposide and Carboplatin Are an Appropriate Choice
This an an open-label study to define the safety profile and the maximum tolerated dose and
confirm the clinical effective dose of palifosfamide-tris given intravenously in combination
with etoposide and carboplatin in a wide range of cancers which etoposide and carboplatin
are normally given. Once the maximum dose of palifosfamide-tris is determined,a Phase II
study using the 3 agents combined will begin.
We found this trial at
4
sites
Click here to add this to my saved trials
Washington University Washington University creates an environment to encourage and support an ethos of wide-ranging...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials